Navigation Links
Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease
Date:11/10/2008

understanding of cysteamine's effects in Huntington's patients and we hope it may lead to a new treatment for this serious, debilitating disease."

The primary endpoint of the Phase II trial will be evaluated using the Unified Hungtington's Disease Rating Scale ("UHDRS"). The secondary endpoint will measure brain-derived neurotrophic factor ("BDNF") levels, known to be deficient in Huntington's patients. A preclinical study published by Drs. Sandrine Humbert and Frederic Saudou from the Curie Institute demonstrated a potential mechanism for cysteamine in an in vivo preclinical Huntington's model that showed increased brain and blood levels of BDNF. The Curie Institute will participate in the clinical trial by determining the BDNF levels in the patients.

About Huntington's Disease

Huntington's is a rare, progressive, and hereditary neurological disease that often leads to death within 15 to 20 years after diagnosis. The disease is thought to affect as many as 20,000 patients in the U.S. There is no currently available drug that targets the defective gene believed to cause Huntington's, which results in the degeneration of certain nerve cells in the brain. The disease is characterized by uncontrollable movements and mood swings or depression, followed by dementia.

About Cysteamine and DR Cysteamine

Cysteamine is approved for sale by the FDA and European Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), a rare, genetic lysosomal storage disease. DR Cysteamine is designed as an enterically coated, proprietary oral formulation of cysteamine to potentially reduce dosing frequency and gastrointestinal side effects.

Raptor obtained an exclusive, worldwide license from the University of California, San Diego ("UCSD") for the development of cysteamine and DR Cysteamine for a number of potential indications including Huntington's, cystinosis, non-alcoholic steatohepatitis ("NASH") and Batten Disease. Raptor is
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update on Targeting Platforms
2. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
5. Raptor Pharmaceuticals Provides Update of Product Programs
6. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
7. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
8. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
11. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... OAKS, Calif., April 21, 2015 Amgen (NASDAQ: ... first quarter of 2015. Key results include: , ... of 2014 to $5,033 million, with 12 percent product ... Prolia ® (denosumab), EPOGEN ® (epoetin alfa), ... Unfavorable changes in foreign exchange rates impacted total revenue ...
(Date:4/21/2015)... , 21. April 2015  CorTechs Labs, ... quantitative Analyse des Hirnvolumens freut sich, eine ... Pharmaunternehmen, bekannt geben zu können. Die Unternehmen ... des Hirnvolumens zusammenarbeiten, der die Identifizierung, Messung ... Patienten mit multipler Sklerose als Ziel hat. ...
(Date:4/21/2015)... -- Lincoln Computer Services has taken a proactive approach to ... LCS donated 10 laptops and carts to the Good ... Home at Riverdale by RiverSpring ... is a creative, non-pharmacological approach to Alzheimer,s care that ... in the morning, start their day off in a ...
Breaking Medicine Technology:Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 2Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 3Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 4Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 5Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 6Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 7Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 8Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 9Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 10Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 11Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 12Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 13Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 14Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 15Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 16Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 17Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 18Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 19CorTechs Labs kündigt Partnerschaft für die Bereitstellung umfassender Lösungen zur Quantifizierung des Verlustes von Hirnvolumen bei multipler Sklerose an 2Lincoln Continues Support of the Community: Donates 10 Laptops for Alzheimer's Program 2
... 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it will present updated results from its,Phase 2 ... a,poster discussion session at the International Association for ... on Lung Cancer in Seoul, Korea.,Details follow: ...
... - Positive Phase 2 Clinical Trial Results from PI-88 in ... $92.4 million in Raised Capital Highlight the Year ... PGL; Nasdaq: PGLA) today released its,financial results for the fiscal ... * Announced positive results from a Phase 2, 172 ...
Cached Medicine Technology:Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer 2Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer 3Progen Pharmaceuticals Announces Fiscal 2007 Financial Results 2Progen Pharmaceuticals Announces Fiscal 2007 Financial Results 3
(Date:4/21/2015)... April 21, 2015 Displays & Exhibits, ... in the trade show exhibit building industry, announced a ... sales offices of Absolute Exhibits in Tustin, California.“It is ... shoppers to observe the variation in quality as offered ... Exhibits,” explained Zenos Adduru. Mr. Adduru is the new ...
(Date:4/21/2015)... San Francisco, CA and Orlando, FL (PRWEB) April ... for Behavioral Health (National Council) will honor Dina ... Support Services for PREP (Prevention and Recovery in ... the National Council Award of Excellence: Peer Specialist ... NatCon15 awards ceremony, known as the Oscars of ...
(Date:4/21/2015)... Henry Mayo Newhall Hospital, located in ... to automatically send continuation of care documents (CCDs). ... improve communication with clinics and other ambulatory practices, they ... solution. , “Provider Alert will enable the physician ... they need to provide continuing care in real time,” ...
(Date:4/21/2015)... April 21, 2015 Grafika is pleased ... printer, Offset Impressions. , “We’re excited about ... of printing capabilities and knowledgeable team members,” according to ... allows us to offer an ever wider breadth of ... packaging, and specialty services we already offer. It ...
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 22, 2015 ... Pipeline Review, H1 2015” provides comparative analysis ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report with TOC ... , The report also reviews key players ...
Breaking Medicine News(10 mins):Health News:Displays & Exhibits Reveals Tustin, California Showroom Under New Management 2Health News:The National Council for Behavioral Health Honors Felton Institute’s PREP Program Coordinator with Prestigious Peer Specialist of the Year Award 2Health News:The National Council for Behavioral Health Honors Felton Institute’s PREP Program Coordinator with Prestigious Peer Specialist of the Year Award 3Health News:The National Council for Behavioral Health Honors Felton Institute’s PREP Program Coordinator with Prestigious Peer Specialist of the Year Award 4Health News:Henry Mayo Newhall Hospital to Improve Ambulatory Information Sharing with Summit Healthcare's Summit Provider Alert 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4
... losing in a way that's making other communities in the ... a town of 80,000 outside Boston, have been taking part ... eating habits that stay with them throughout their lives. As ... those in nearby towns, and as they learn to eat ...
... felt on the world fashion map, it is attracting ... the ramp here but also try their luck in ... matured as designers stopped copying Western motifs blindly. India ... as becoming a profitable business destination for international buyers. ...
... functions may be vulnerable to Alzheimers disease if they ... blood vessels in the brain, says a study ... in the Journal of Neuroimaging, also suggests that people ... the disease than their peers. ,Alzheimers ...
... Elevated CO2 is considered to be a serious catalyst ... the ecosystem , including the insect-plant food chain link.Safeguarding ... and national economies. ,In research to be presented ... Plant Biologists in Chicago (July 7-11, 2007), scientists will ...
... who received the world's first face transplant 18 months ago said ... herself in the mirror with a combination of sadness and wonder. ... who have a face, a smile, facial expressions which allow them ... in an interview published in Saturday's edition of Le Monde. ...
... Africa on Friday after they came into contact with an ... ,Inspector Juanita Kilian said police had received a complaint ... of Johannesburg, about a "suspicious" envelope, she told public radio. ... this stage we cannot confirm that the contents were anthrax," ...
Cached Medicine News:Health News:Somerville, A Town Committed to Tackle Obesity Among Kids 2Health News:Somerville, A Town Committed to Tackle Obesity Among Kids 3Health News:Indian Fashion Beckons International Models 2Health News:Elevated Carbondioxide may Have Negative Impact on Ecosystem 2Health News:World's First Face Transplant Patient Feels She is Alive Again 2
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
... Digisonics has set the standard in ... review station, the only fully integrated ... multi-modality reporting., ,DigiView cardiology solutions bring ... professional reporting choices, an integrated clinical ...
... The menu-driven Vapro osmometer determines osmolality ... natural equilibrium. ,What you don't get are ... particles, or other conditions that interfere with ... percent in the clinical range) Vapro osmometer ...
Medicine Products: